Clinical Trials on Myeloproliferative Disorders

Total 144702 results

Incyte Corporation

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

MPN (Myeloproliferative Neoplasms)

United States, France, United Kingdom, Spain, Canada, Japan, Germany, Switzerland, Belgium, Austria, Italy
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Cholecalciferol in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
European Working Group of MDS in Childhood

Unknown

Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome

Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

Germany
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes

Myelodysplastic Syndromes | Myelodysplastic/Myeloproliferative Neoplasms

United States, Canada, Australia, Puerto Rico
Stanford University

Terminated

Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry

Myeloproliferative Disorders | Myeloproliferative Disorders (MPD)

United States
Incyte Corporation

Terminated

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

MPN (Myeloproliferative Neoplasms)

United States
Fallon Clinic

Completed

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Anemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
CTI BioPharma
National Cancer Institute (NCI)

Terminated

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Institut Paoli-Calmettes

Not yet recruiting

Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning (BUSEQ)

Acute Leukemia | Myeloproliferative Neoplasm | Mielodysplasic Syndrome
Inge Marie Svane

Completed

CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms

Essential Thrombocythemia | Myelofibrosis | Myeloproliferative Neoplasm, Unclassifiable

Denmark
Yale University
National Cancer Institute (NCI)

Completed

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Neoplasms

United States
Incyte Corporation

Not yet recruiting

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms
Hospital Israelita Albert Einstein
Federal University of Minas Gerais; Federal University of São Paulo; Hospital... and other collaborators

Recruiting

Registry of Philadelphia-Negative Myeloproliferative Neoplasms (MPN)

Hematologic Diseases

Brazil
Weill Medical College of Cornell University
Astex Pharmaceuticals, Inc.

Completed

A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms

Myeloproliferative Neoplasms

United States
Italfarmaco

Completed

Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases

Myeloproliferative Diseases

Italy
John Mascarenhas
National Cancer Institute (NCI); Incyte Corporation; Myeloproliferative Disorders-Research...

Completed

Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML

Myeloproliferative Neoplasms

United States
Memorial Sloan Kettering Cancer Center

Completed

The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies

Lymphoma | Metastatic Solid Tumor | Myeloproliferative Neoplasms (MPN)

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Stanford University
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
M.D. Anderson Cancer Center

Not yet recruiting

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Myeloproliferative Neoplasm | Myelodysplastic Neoplasm | Pathway Mutant Myelodysplastic Syndromes

United States
University of Washington

Completed

Interleukin-2 in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Incyte Corporation

Completed

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

MPN (Myeloproliferative Neoplasms)

United States, Puerto Rico
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

Myelodysplastic Syndromes | Myeloproliferative Neoplasm

United States
University of Milano Bicocca

Recruiting

Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.

Inflammatory Markers | Myeloproliferative Disease

Italy
Children's Oncology Group
National Cancer Institute (NCI)

Completed

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

Unspecified Childhood Solid Tumor, Protocol Specific | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Neoplasms

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis

Chronic Myeloproliferative Disorders

United States, United Kingdom, France
Incyte Corporation

Recruiting

A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms (LIMBER)

Myeloproliferative Neoplasms

United States
Janssen Research & Development, LLC
Bristol-Myers Squibb

Recruiting

A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

Myeloproliferative Neoplasms

United States, United Kingdom
Chang Gung Memorial Hospital

Active, not recruiting

Registry of Patients With MPNs in Taiwan

Myeloproliferative Neoplasms

Taiwan
University of Ulm

Completed

Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage

Myeloproliferative Neoplasms

Germany
University of Chicago

Not yet recruiting

Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation (MPN)

Myeloproliferative Neoplasms

United States
Incyte Corporation

Recruiting

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (LIMBER)

Myeloproliferative Neoplasms

Spain, Japan, France, Italy, Germany, Australia, United Kingdom, Denmark, Canada
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms

China
Assistance Publique - Hôpitaux de Paris

Unknown

Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders (CTIM3)

Myeloproliferative Neoplasms

France
National Cancer Institute (NCI)

Completed

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Neoplasms

United States
Fred Hutchinson Cancer Center
ImmunoGen, Inc.

Recruiting

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Mixed Phenotype Acute Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm

United States
Fondazione per la Ricerca Ospedale Maggiore

Completed

European Registry for Myeloproliferative Neoplasms (MPNs) - Update of ERNEST Study (ERNEST)

Myelofibrosis

Italy, Spain, Sweden
University Health Network, Toronto

Completed

Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm (DSC-SR)

Myelodysplastic/Myeloproliferative Neoplasm | Allogeneic Hematopoietic Cell Transplant | Steroid Refractory GVHD

Canada
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
National Cancer Institute (NCI)

Not yet recruiting

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Myelodysplastic Syndromes

United States
Hospital Israelita Albert Einstein

Unknown

Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation

Acute Leukemia | Immunodeficiency | Chronic Leukemia | Lymphoproliferative Disease | Myeloproliferative Disease

Brazil
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
National Cancer Institute (NCI)

Completed

Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Unspecified Adult Solid Tumor, Protocol Specific | Myelodysplastic/Myeloproliferative Neoplasms

United States

Clinical Trials on Myeloproliferative Disorders

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations